Predict your next investment

Endowment
cysticfibrosis.org.uk

See what CB Insights has to offer

Investments

1

Portfolio Exits

1

Partners & Customers

4

About Cystic Fibrosis Trust

The Cystic Fibrosis Trust invests money into cystic fibrosis research.

Cystic Fibrosis Trust Headquarter Location

1 Aldgate Road Second Floor

London, England, EC3N 1RE,

United Kingdom

+0300 373 1000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Cystic Fibrosis Trust News

Northern Ireland Reaches Deal With Vertex for Access to Kaftrio

Aug 3, 2020

(1) The agreement follows similar ones that the company made recently with England and Wales . “We’re delighted to see Northern Ireland and Vertex Pharmaceuticals reach a deal on Kaftrio, ensuring that hundreds of people across Northern Ireland will soon get access to this truly life-saving medicine,” Keith Brownlee, director of policy, programs, and support at the Cystic Fibrosis Trust , said in a  press release . Kaftrio is a triple combination therapy,  containing 100 mg of elexacaftor, 50 mg of tezacaftor, and 75 mg of ivacaftor . It is meant to be taken with Kalydeco  (150 mg), also marketed by Vertex. A similar triple combination therapy named  Trikafta has been approved in the U.S. Under the agreement, patients ages 12 and older and who have either two copies of the F508del mutation, or one copy of F508del mutation and one copy of a minimal function mutation in the CFTR gene (the gene defective in CF) will be eligible for Kaftrio treatment. The F508del mutation is the most common CF-causing mutation. According to the  Cystic Fibrosis Trust , this agreement marks a big moment for the CF community. The Trust, along with CF patients and advocates, have long campaigned for greater access to life-saving therapies. Writing in a blog on the CF Trust’s website, Brownlee stated in late June that “Kaftrio will likely receive its marketing authorisation in late summer or early autumn” from the European Medicines Agency (EMA). In June, the EMA’s Committee for Medicinal Products for Human Use  issued a positive opinion on the use of Kaftrio , in combination with Kalydeco , as a treatment for CF. This positive opinion was based on results from the AURORA clinical trials ( NCT03525444 and NCT03525548 ), which showed that Kaftrio significantly improved lung function and reduced disease exacerbations in CF patients. “While this is a special moment, there is more to do, and we will not stop until everyone with cystic fibrosis across the UK has access to life saving drugs,” Brownlee said. Liam McHugh, 58, from County Tyrone in Northern Ireland, has a daughter who was born with cystic fibrosis more than 28 years ago. “Ever since I’ve dedicated my life to fundraising and campaigning for life-saving drugs for people with the condition,” he said. “So news that Kaftrio will be available to people in Northern Ireland is incredible and is going to extend lives.” Author Details

Cystic Fibrosis Trust Investments

1 Investments

Cystic Fibrosis Trust has made 1 investments. Their latest investment was in Enterprise Therapeutics as part of their Grant on April 4, 2017.

CBI Logo

Cystic Fibrosis Trust Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/5/2017

Grant

Enterprise Therapeutics

$0.12M

Yes

2

Date

4/5/2017

Round

Grant

Company

Enterprise Therapeutics

Amount

$0.12M

New?

Yes

Co-Investors

Sources

2

Cystic Fibrosis Trust Portfolio Exits

1 Portfolio Exit

Cystic Fibrosis Trust has 1 portfolio exit. Their latest portfolio exit was Enterprise Therapeutics on October 07, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/7/2020

Acquired

$99M

1

Date

10/7/2020

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

1

Cystic Fibrosis Trust Partners & Customers

4 Partners and customers

Cystic Fibrosis Trust has 4 strategic partners and customers. Cystic Fibrosis Trust recently partnered with Beam on October 10, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

10/3/2017

Partner

United Kingdom

Pactster offers free exercise therapy to better lives of people with cystic fibrosis

Pactster , a company providing community-based online workouts for people with specific health conditions , is excited to announce a new partnership with the Cystic Fibrosis Trust in the UK .

1

8/31/2017

Partner

Canada

Subscribe to see more

Subscribe to see more

10

6/9/2017

Partner

Subscribe to see more

Subscribe to see more

10

4/5/2017

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

Date

10/3/2017

8/31/2017

6/9/2017

4/5/2017

Type

Partner

Partner

Partner

Partner

Business Partner

Country

United Kingdom

Canada

United Kingdom

News Snippet

Pactster offers free exercise therapy to better lives of people with cystic fibrosis

Pactster , a company providing community-based online workouts for people with specific health conditions , is excited to announce a new partnership with the Cystic Fibrosis Trust in the UK .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

Cystic Fibrosis Trust Team

2 Team Members

Cystic Fibrosis Trust has 2 team members, including former Chief Executive Officer, Nigel Barker.

Name

Work History

Title

Status

Nigel Barker

Chief Executive Officer

Former

Matthew Reed

Birmingham City Council, and The Children's Society

Chief Executive Officer

Former

Name

Nigel Barker

Matthew Reed

Work History

Birmingham City Council, and The Children's Society

Title

Chief Executive Officer

Chief Executive Officer

Status

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.